At a glance
ClinicalIndex Comparison RecordN/ACompleted· 240 enrolled
Drug / intervention
MIRCERAdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Observational Study of MIRCERA in Users of Self-Application and Multidose Systems
In Brief
An observational study evaluating MIRCERA for Renal Anemia of Chronic Kidney Disease. Completed, enrolled 240 participants across 1 site.
Detailed Summary
This non-interventional, observational study investigates the efficiency, safety and acceptance of MIRCERA in participants, who received erythropoiesis stimulating agent (ESA) using a self-application system. For each participant, the investigator documents 9 months of treatment with Mircera with respect to efficacy, safety and acceptance.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Anemia of Chronic Kidney Disease
CountriesGermany
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2009
Primary CompletionNov 2010
First PostedSep 2015
TodayJul 2026
First PostedSep 3, 2015
Enrollment StartJan 1, 2009
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 10.8 years ago
Interventions
MIRCERAdevice
Methoxy polyethylene glycol epoetin beta (0.6 mcg/kg q2w) will be administered using MIRCERA ready-to-use-syringes up to 9 months.